Corporate Greed Case Study: Novo Nordisk and Its Impact on Public Health

The Patient in the Pharmacy Line

For millions of Americans, the pharmacy counter is a site of anxiety. It’s where we confront the staggering cost of medications we need to manage chronic conditions like cancer, diabetes, or heart disease. We are the human face of a crisis fueled by corporate decisions made in boardrooms hundreds of miles away. These patients, who need drugs like Ozempic, Saxenda, and Victoza to live healthier lives, are the victims in a story of an alleged corporate overreach by the pharmaceutical giant Novo Nordisk.

According to a 2024 scathing letter from the federal government, these patients and the entire American healthcare system are paying artificially high prices.

The reason? A corporate strategy that allegedly uses a government regulatory system not to foster innovation, but to erect illegal roadblocks against the affordable, generic competition that people desperately need. This is a story about an exploitative economic system that is being weaponized against the most vulnerable members of society.

The Corporate Playbook: How the Harm Was Done

The Federal Trade Commission claims that Novo Nordisk has been engaged in a calculated and harmful corporate strategy: improperly listing patents in a federal database known as the “Orange Book”. This playbook, while seemingly bureaucratic, has devastating real-world consequences.

Here is how the alleged scheme works:

• The Weaponization of a List: The Orange Book is meant to be a simple registry of approved drugs and their associated patents. However, brand-name drug companies like Novo Nordisk have a legal obligation to list their patents accurately.
• The “Improper” Listing: The FTC believes Novo Nordisk has listed numerous patents for Ozempic, Saxenda, and Victoza that are either inaccurate or irrelevant to the drugs themselves.
• The Automatic Barrier: When a generic drug manufacturer is ready to bring a cheaper alternative to market, these improper listings act as a tripwire. They can trigger an automatic 30-month stay, effectively pausing the FDA’s approval process for two and a half years.
• Intimidation Through Litigation: Beyond the automatic delay, the sheer cost of challenging these junk patents in court can discourage or even prevent generic companies from trying to compete in the first place.

This isn’t an accident. The FTC letter frames this as a deliberate strategy of “unfair methods of competition” designed to extend a company’s monopoly long after it should have expired.

A Cascade of Consequences: The Real-World Impact

The fallout from delaying affordable medicine is a public health catastrophe that harms the most vulnerable and puts a strain on the entire nation.

Public Health & Safety at Risk

When affordable generic alternatives are blocked from the market, patients are harmed directly. They are forced to pay exorbitant brand-name prices, leading many to ration their medication, skip doses, or go without it entirely.

For drugs that manage serious conditions like diabetes, this can lead to devastating health complications, hospitalizations, and even death. This corporate strategy creates a two-tiered system of care: one for those who can afford the monopoly price, and another for those who suffer the consequences.

Economic Ruin for Families and the Nation

The economic damage is immense. Even brief delays in generic competition cost patients and the healthcare system billions of dollars.

• Families are drained of their savings to pay for life-saving drugs.
• Insurance premiums for everyone rise as insurers are forced to cover the inflated costs.
• Government programs like Medicare and Medicaid pay billions more, a cost borne by every taxpayer.

This is an absolutely enormous wealth transfer from the pockets of patients, families, and taxpayers directly into the coffers of a pharmaceutical giant.

A System Designed for This: Profit, Deregulation, and Power

This section is an analysis of the facts presented in the legal document.

The alleged actions of Novo Nordisk are a predictable, if egregious, outcome of a neoliberal economic system that sanctifies profit above all else.

The patent system, and the Orange Book in particular, was created with the intention of balancing the need to reward innovation with the public’s right to access affordable medicine. However, in a system where corporations are legally bound to maximize shareholder value, any rule or regulation is seen not as a civic duty, but as a strategic obstacle to be overcome or a tool to be exploited.

Novo Nordisk’s alleged behavior is the rational endpoint of this logic.

If a company like Novo Nordisk can extend its multi-billion-dollar monopoly for another 30 months by simply filing a piece of paper—however improper—the financial incentive to do so is overwhelming.

The harm to public health is an externality, a cost borne by society, not by the company’s balance sheet. The FTC’s intervention is a rare and necessary check on a system where corporate power has been allowed to weaponize the very laws meant to regulate it.

Dodging Accountability: How the Powerful Evade Justice

This FTC letter is a critical first step, but it is not justice in itself. For years, as the FTC notes, it has tried to combat these anticompetitive practices. Yet the behavior persists. The immediate consequence for Novo Nordisk is not a fine or a penalty, but merely a warning that it may be investigated further.

This highlights a deep flaw in our system of accountability.

The profits gained from years of delaying generic competition can often far outweigh the eventual fines, which corporations may come to see as an acceptable cost of doing business. The process is slow, allowing companies to benefit from their alleged misconduct for years before facing even the threat of consequences.

Reclaiming Power: Pathways to Real Change

The FTC’s aggressive new stance, evidenced by this letter and its accompanying policy statement, represents a crucial pathway to reclaiming power for the American public. By publicly calling out these “improper listings” and threatening action under Section 5 of the FTC Act, the agency is signaling that the era of lax enforcement may be over.

Real change requires regulators to follow through on these threats with significant, painful penalties that make these strategies unprofitable.

It requires simplifying the process for challenging and removing junk patents from the Orange Book, so that competition is not delayed by years of litigation. And it requires constant public pressure to remind lawmakers and regulators that the health of the people must take precedence over the profits of any single corporation.

Conclusion: A Story of a System, Not an Exception

The FTC’s warning to Novo Nordisk is a window into a much larger crisis. A crisis of antiturst where a miniscule number of corporations control an outsized portion of our lives. A story of a late-stage capitalistic system that has allowed the rules of fair commerce to be twisted into tools of monopoly and oppression.

The fight over Ozempic patents is a battle on the front lines of a larger war for economic and social justice in America. It’s a fight to decide whether life-saving medicine is a commodity to be exploited for maximum profit, or a public good that should be accessible to all.

Disclaimer: All factual claims in this article pertaining to the regulatory letter were derived from a document sent by the Federal Trade Commission to Novo Nordisk Inc. on April 30, 2024.

Eli Lilly also got hit with a similar letter at the around the same time, but I don’t want to do too (two) many articles on this since they’re both basically saying the same thing– just with different companies, different drugs, and different illnesses. If you want you can pretend that I did actually do an expose on Eli Lilly and just swap some names around in your head while rereading this article kek